Your browser doesn't support javascript.
loading
Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer.
Elfiky, Aymen A; Aziz, Saadia A; Conrad, Patricia J; Siddiqui, Summar; Hackl, Wolfgang; Maira, Michel; Robert, Camp L; Kluger, Harriet M.
Afiliação
  • Elfiky AA; Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, United States of America.
J Transl Med ; 9: 133, 2011 Aug 11.
Article em En | MEDLINE | ID: mdl-21834980
ABSTRACT

BACKGROUND:

PI3K and mTOR are key components of signal transduction pathways critical for cell survival. Numerous PI3K inhibitors have entered clinical trials, while mTOR is the target of approved drugs for metastatic renal cell carcinoma (RCC). We characterized expression of p85 and p110α PI3K subunits and mTOR in RCC specimens and assessed pharmacologic co-targeting of these molecules in vitro.

METHODS:

We employed tissue microarrays containing 330 nephrectomy cases using a novel immunofluorescence-based method of Automated Quantitative Analysis (AQUA) of in situ protein expression. In RCC cell lines we assessed synergism between PI3K and mTOR inhibitors and activity of NVP-BEZ235, which co-targets PI3K and mTOR.

RESULTS:

p85 expression was associated with high stage and grade (P < 0.0001 for both). High p85 and high mTOR expression were strongly associated with decreased survival, and high p85 was independently prognostic on multi-variable analysis. Strong co-expression of both PI3K subunits and mTOR was found in the human specimens. The PI3K inhibitor LY294002 and rapamycin were highly synergistic in all six RCC cell lines studied. Similar synergism was seen with all rapamycin concentrations used. NVP-BEZ235 inhibited RCC cell growth in vitro with IC(50)s in the low ηM range and resultant PARP cleavage.

CONCLUSIONS:

High PI3K and mTOR expression in RCC defines populations with decreased survival, suggesting that they are good drug targets in RCC. These targets tend to be co-expressed, and co-targeting these molecules is synergistic. NVP-BEZ235 is active in RCC cells in vitro; suggesting that concurrent PI3K and mTOR targeting in RCC warrants further investigation.
Assuntos

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Serina-Treonina Quinases TOR / Terapia de Alvo Molecular / Inibidores de Fosfoinositídeo-3 Quinase / Neoplasias Renais Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: J Transl Med Ano de publicação: 2011 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Serina-Treonina Quinases TOR / Terapia de Alvo Molecular / Inibidores de Fosfoinositídeo-3 Quinase / Neoplasias Renais Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: J Transl Med Ano de publicação: 2011 Tipo de documento: Article